This report covers the 68 geographical markets and provides an Excel-based forecast model for the obesity market through 2031.
Across the 68 markets, sales in the obesity market were $12.3 billion in 2021, growing to $206.5 billion in 2031.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 85% and 84% of 68-market sales in 2021 and 2031, respectively.
Across the 68 markets, sales in the obesity market were $12.3 billion in 2021, growing to $206.5 billion in 2031.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 85% and 84% of 68-market sales in 2021 and 2031, respectively.
Scope
- This publication is an expanded version of the Excel model containing the patient-based forecast sales for obesity, covered in the analyst’s report “Obesity: Seven -Market Drug Forecast and Market Analysis Update”, published in January 2025.
- In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 61 geographical markets (61M), totaling 68 markets (68M).
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM obesity therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- About the Analyst
1 Executive Summary
2 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk
- Eli Lilly
- Boehringer Ingelheim
- Zealand Pharma
- Amgen
- Structure Therapeutics
- Viking Therapeutics
- Veru Inc
- Altimmune
- Metsera
- Rose Pharma
- Empros Pharma
- Lipocine Inc
- Glyscend Inc
- Rhythm Pharmaceuticals
- Roche
- H2-Pharma
- Chelapharm
- Vivus Inc.
- Orexigen Therapeutics
- Currax Pharmaceuticals